NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · LARGE CAP
Neogen Corporation NEOG
16 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$894.7M
▼ 3.2% vs FY2023
EPS · FY24
$-5.03
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-41.9%
Net margin · FY24
-122.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 894.7M
Revenue, FY2024 · full 16-year series below
Revenue
Net income
The company lost 122 cents on every revenue dollar this year.
Per share
USD -5.03
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-41.9%
Return on equity, FY2024
ROE
Operating margin-118.6%
Net margin-122.1%
Return on assets-27.3%
Each USD of equity lost 42 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+16.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+19.3%
+16.4%
+12.2%
+13.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.22B
Shares outstanding, FY2024
Change, 5 years+42.2%
Change, 10 years—
The share count grew 42% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.4B
total assets, end of FY2024
Total assetsUSD 3.4B
EquityUSD 2.1B
CashUSD 129.0M
Gross debtUSD 894.1M
Net debtUSD 765.1M
Current ratio3.32×
Net debt stands at 37% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.9
0.9
0.8
0.5
0.5
0.4
0.4
0.4
0.4
0.3
0.3
0.2
0.2
0.2
0.2
0.1
Operating income $B
−1.1
0.1
0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.9
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
Income tax $B
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−1.1
−0.0
−0.0
0.0
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−5.03
−0.04
−0.12
0.45
0.57
0.56
0.57
1.21
0.86
0.72
0.90
0.76
0.75
0.62
0.96
0.76
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−41.9
−0.3
−1.1
5.6
7.8
8.7
10.0
12.2
10.0
9.7
10.2
10.0
11.4
11.0
12.1
·
Shares out B
0.22
0.22
0.22
0.11
0.11
0.11
0.05
0.05
0.05
0.04
0.04
0.04
0.04
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
62 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed